A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

@article{Friess2006ARM,
  title={A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer},
  author={Helmut Friess and Jan Michael Langrehr and Helmut Oettle and Jochen Raedle and Marco Niedergethmann and Christian Dittrich and Dieter Kurt Hossfeld and Herbert Stoeger and Bart Neyns and Peter Herzog and Pascal Piedbois and Frank Dobrowolski and Werner Scheithauer and Robert Edward Hawkins and Frieder Katz and Peter Balcke and Jan Baptist Vermorken and Simon Van Belle and Neville G Davidson and Albert Abad Esteve and Daniel E. Castellano and Joerg Kleeff and Adrien A. Tempia-Caliera and Andreas Kovar and Johannes Nippgen},
  journal={BMC Cancer},
  year={2006},
  volume={6},
  pages={285 - 285}
}
Anti-angiogenic treatment is believed to have at least cystostatic effects in highly vascularized tumours like pancreatic cancer. In this study, the treatment effects of the angiogenesis inhibitor Cilengitide and gemcitabine were compared with gemcitabine alone in patients with advanced unresectable pancreatic cancer. A multi-national, open-label, controlled, randomized, parallel-group, phase II pilot study was conducted in 20 centers in 7 countries. Cilengitide was administered at 600 mg/m2… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Cancer statistics, 2005.

CA: a cancer journal for clinicians • 2005

Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy.

International journal of radiation oncology, biology, physics • 2003
View 1 Excerpt

Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine

C Ziske, C Schlie, +3 authors J Strehl
Br J Cancer • 2003
View 1 Excerpt

Specific alpha v integrin receptors modulate K1735 murine melanoma cell behavior.

Biochemical and biophysical research communications • 2003
View 1 Excerpt

Similar Papers

Loading similar papers…